Skip to content

Neutral Aurobindo Pharma; target of Rs 500: Motilal Oswal

Motilal Oswal recommended Neutral rating on Aurobindo Pharma with a target price of Rs 500 in its research report dated November 14, 2022.

Read More

Leave a Reply

Generated by Feedzy
en_USEnglish
%d bloggers like this: